Select the surgical approach and route for gynaecological procedures and apply energy sources safely

In one line

Choosing how to operate is a graded decision, not a reflex: for benign hysterectomy the evidence ranks vaginal first where feasible, laparoscopic next, open last, and the route is justified from the patient's anatomy and the trial data rather than from the kit on the shelf — while for early cervical cancer that whole instinct reverses, because open radical hysterectomy out-survives minimally invasive surgery. Both rest on a working knowledge of how the energy device in your hand actually injures tissue.

This chapter assumes the operative groundwork — basic laparoscopic and abdominal anatomy, how to consent and prepare a patient, and the perioperative bundle — and concerns the choice of a route and an energy strategy. Pre-operative assessment, consent on the Montgomery standard and the WHO checklist sit with perioperative care and safe surgery; the haemorrhage, ureteric and visceral injuries that follow a wrong route or a careless device sit with intraoperative and endoscopic-surgery complications; the cervical-cancer route reversal is developed for the oncology setting in cervical-cancer. The focus here is the decision and the device.

Mechanism & pathophysiology

Two quite different mechanisms underlie route and energy selection, and they must be kept apart. The first is the biomechanics of access — why route changes outcome at all. The second is the biophysics of energy — how an electrosurgical or ultrasonic device cuts, coagulates and, when misused, burns something you never touched.

Why route changes outcome. A hysterectomy can reach the uterus three ways: through the vagina (no abdominal wall breached), through the abdominal wall under laparoscopic vision (small incisions, pneumoperitoneum), or through a laparotomy. The abdominal wall is the single biggest source of post-operative morbidity — wound infection, dehiscence, incisional hernia, pain that delays mobilisation and so feeds venous thromboembolism and atelectasis. Every step away from a large abdominal incision removes a tranche of that morbidity, which is the whole physiological argument for "minimally invasive whenever feasible." But access is not free: laparoscopy substitutes the abdominal wound for the hazards of pneumoperitoneum and a longer, more technically exposed ureteric dissection, and the vaginal route, while it breaches no abdominal wall at all, demands a mobile uterus of operable size and adequate vaginal access. So the route hierarchy is a trade between wound morbidity (worst with open) and access/exposure morbidity (the ureter is more vulnerable laparoscopically) — and the patient's own anatomy decides where that trade lands.

The oncological exception has a different mechanism. In cervical cancer the question is not wound morbidity but tumour dissemination. The leading hypotheses for why minimally invasive radical hysterectomy did so much worse are tumour-spillage and gas-related dissemination: the uterine manipulator can breach a friable tumour and seed the peritoneum, and the circulating CO₂ pneumoperitoneum may aerosolise or redistribute malignant cells, while colpotomy under pneumoperitoneum exposes the open vaginal cuff to that environment. None of these mechanisms operates in benign surgery — which is exactly why minimally invasive surgery is right for a fibroid uterus and wrong for an invasive cervical cancer. The mechanism, not the instrument, sets the rule.

The biophysics of energy. Electrosurgery passes high-frequency alternating current through tissue; the heat is generated in the tissue by its resistance, not by a hot element. What the current does depends on the waveform and on current density (current per unit area), which is why a fine electrode tip vaporises while a broad return pad does nothing.

• Monopolar current runs from the active electrode, through the patient, to a dispersive return pad. A cut waveform is a continuous low-voltage sinusoid that heats cell water explosively to vaporise and divide tissue; a coagulation waveform is interrupted high-voltage bursts that heat more slowly to desiccate and fulgurate, sealing small vessels. High voltage is the troublemaker — coag mode drives the stray-current phenomena below.
• Bipolar confines the circuit between the two limbs of the instrument: current passes only through the tissue grasped, so there is no return pad and far less stray energy. It coagulates and seals but classically does not cut. Advanced bipolar vessel-sealing devices add pressure and feedback-controlled energy to denature collagen and elastin into a seal that reliably holds vessels up to roughly 7 mm, with less lateral spread than open coagulation.
• Ultrasonic ("harmonic") devices are not electrosurgical at all: a blade vibrating tens of thousands of times a second (~55 kHz) breaks hydrogen bonds and generates frictional heat, cutting and coagulating at lower temperatures (~50–100 °C vs >150 °C for electrosurgery), which means less smoke, less char and a narrower zone of lateral thermal spread — useful near the ureter and bowel. The cost is that the active blade stays hot for several seconds after activation ends, so a careless backstroke can burn tissue the surgeon thought was safe.

The single quantity that ties these together is lateral thermal spread — how far heat travels from the point of application into adjacent tissue. It is widest with open monopolar coagulation, intermediate with standard bipolar, and narrowest with advanced vessel-sealing and ultrasonic devices; it is also dose-dependent (longer activation, higher power, repeated application on the same spot all widen it). This is not academic: a thermal margin of a few millimetres is the difference between sealing a uterine pedicle and stricturing a ureter that lay just lateral to it.

The hazards that matter most are the ways monopolar energy injures tissue the surgeon never deliberately touched, and they are best understood mechanistically. Insulation failure — a breach in the shaft's insulation, most often in the distal third that lies out of the camera's view — lets current arc to whatever the bare metal contacts. Direct coupling — the activated electrode touches another metal instrument (a grasper, the laparoscope), which becomes live and burns wherever it sits. Capacitive coupling — current is induced across intact insulation into a nearby conductor; it is worst with coagulation mode, with an open circuit (electrode activated without touching tissue), with high-voltage generators, and when a metal cannula is isolated from the abdominal wall by a plastic anchor so the induced charge cannot dissipate. Each of these can produce a delayed bowel-wall burn that perforates days later, far from the operative field — the classic "no one touched the bowel" thermal injury.

Assessment

Route selection is a structured assessment of the uterus, the pelvis, the pathology and the patient — done before the consent conversation, because it determines what you are consenting her for.

• Uterine size and shape. A small-to-moderate, regular uterus suits the vaginal route; a large, irregular or fixed uterus may not descend or fit through the introitus and pushes you laparoscopic or open. Morcellation to extract a large specimen carries its own oncological caveat (below) and is not a free pass.
• Uterine mobility and descent. Vaginal hysterectomy needs a uterus that moves — some descent, a capacious vagina, an accessible cervix. A nulliparous, immobile uterus with a narrow vagina is the classic reason a vaginal approach is not feasible and laparoscopy becomes the next choice.
• Adnexal pathology and the need for concurrent procedures. A large ovarian mass, suspected endometriosis with frozen pelvis, or the need to inspect the upper abdomen argues for a route that gives upper-pelvic access — laparoscopic or open — over a purely vaginal approach.
• Previous surgery and adhesions. Prior laparotomy, caesarean sections (bladder adherent to a scarred lower segment) or known adhesive disease raise the risk of entry injury and visceral adhesion and may shift the safest route — sometimes towards open, where adhesiolysis is easier and safer than blind laparoscopic entry.
• Malignancy — the question that changes everything. Confirmed or suspected gynaecological malignancy moves the decision out of the benign hierarchy: invasive cervical cancer mandates open radical surgery (see the evidence section); a uterus that might harbour an occult sarcoma must never be power-morcellated, because morcellating an undiagnosed leiomyosarcoma upstages it and worsens survival.
• The patient and the system. Body habitus, cardiorespiratory reserve (can she tolerate steep Trendelenburg and a long pneumoperitoneum?), her informed preference, and — honestly stated for South Africa — what the site can actually deliver: a functioning laparoscopic stack, a surgeon credentialed in that route, and theatre time. A route that is "best" in a textbook but unavailable or unsafe in your hands at 02:00 in a district theatre is not the right route for that patient that night.

Interpreting all of this, the operative question is rarely "open or laparoscopic?" in isolation; it is "what is the least morbid route that safely accomplishes the specific operation in this specific patient in this specific theatre?" — and the choice holds up only when the factor that drove it can be named.

The anatomy that makes any route safe. Whatever the approach, the operation is dissection through avascular planes with the ureter held in mind. The paravesical and pararectal spaces are developed to isolate and define the cardinal (lateral cervical) ligament between them; opening them lets the surgeon clamp pedicles under vision rather than blindly in bleeding tissue, which is the structural reason a deliberate dissection is also a haemostatic one. The ureter is the structure energy and clamps most often injure: it enters the pelvis crossing the bifurcation of the common iliac artery, runs medial on the leaf of the broad ligament, passes beneath the uterine artery roughly 1.5–2 cm lateral to the cervix ("water under the bridge"), then sweeps anteromedially across the upper vagina to the bladder. Three points on that course — at the pelvic brim, under the uterine artery, and at the vaginal angle — are where it is caught. Knowing this turns "be careful near the ureter" into a specific instruction: skeletonise the uterine artery, lateralise the ureter off the cervix before securing the pedicle, and keep the energy device's thermal margin away from all three danger points.

Management

The decision falls into three frames: immediate (which route, now, for this case) → ongoing (energy strategy and intra-operative discipline) → long-term (de-adoption, governance and where the field is moving).

Immediate — selecting the route

The benign-hysterectomy hierarchy, grounded in the evidence below, runs:

The principle reduces to: minimally invasive whenever feasible, vaginal preferred among the minimally invasive routes, and open kept for when access, safety or oncology demands it. For early cervical cancer, that principle inverts — open radical hysterectomy is standard and laparoscopic/robotic radical hysterectomy is not offered as equivalent.

Ongoing — applying energy safely

Route chosen, the intra-operative work is to use energy deliberately. The principles are short:

• Match the modality to the task. Use the lowest power and the shortest activation that achieves the effect; prefer bipolar or vessel-sealing for haemostasis and reserve high-voltage monopolar coag for when you genuinely need it, because coag mode drives capacitive coupling.
• See the whole working tip. Activate the electrode only when its entire active surface is in view — most stray-energy injuries happen to structures off-screen or behind the active tip.
• Defend against stray current. Inspect insulation before use and discard damaged instruments (insulation failure clusters in the distal third); avoid activating an electrode in an open circuit (touching nothing) and avoid resting it against other metal instruments (direct coupling); use all-metal cannulas rather than metal-isolated-by-plastic to let any induced capacitive charge dissipate to the abdominal wall; consider active-electrode monitoring where available.
• Respect lateral thermal spread near vital structures. Energy seals beyond the visible blanch — keep monopolar and even bipolar a safe margin from the ureter and bowel, and favour ultrasonic or careful bipolar in those planes because their thermal footprint is narrower.
• Work in the avascular spaces and know the ureter's course. Safe pelvic surgery is anatomical, not energetic: develop the paravesical and pararectal spaces to define the cardinal ligament; remember the ureter runs medial in the broad ligament, crosses under the uterine artery ("water under the bridge") about 1.5–2 cm lateral to the cervix, then runs along the upper vagina. Skeletonising or lateralising the ureter under direct vision before applying energy to the uterine pedicle prevents both the mechanical and the thermal injury — and is the reason a named dissection beats a fast one.

Long-term — de-adoption, governance and access

The least glamorous part of this objective is institutional. A unit must be able to stop doing something the evidence has condemned — the post-LACC withdrawal of minimally invasive radical hysterectomy for cervical cancer is the textbook example of evidence-led de-adoption, and a consultant should be able to lead it (audit current practice, retrain to open radical surgery, re-consent the pipeline of patients). It must also govern adoption: a robotic or advanced-energy programme needs credentialing, a learning-curve plan and an honest cost case, not just a new toy. And in South Africa the long-term frame is equity — concentrating high-cost technology at a few tertiary centres while district units lack a working laparoscopic stack widens, rather than narrows, the outcome gap, a tension that any service-level decision has to weigh.

Guidelines compared

The major bodies broadly agree on the benign hierarchy and diverge mainly on robotics and on how prescriptive to be.

Where they genuinely diverge is robotics: none claims superiority for benign disease, but they differ on how permissive to be about its spread given the cost. The recent change worth flagging (≤5 years) is the cervical-cancer reversal — international and SA practice moved from accepting laparoscopic/robotic radical hysterectomy to mandating open radical surgery after LACC.

The evidence & the controversy

Three threads run through this topic, and they must be held apart.

First, the benign route hierarchy is evidence-led, not dogma. The eVALuate study showed that laparoscopic hysterectomy carries more major complications than the open abdominal route (11.1% vs 6.2%) while delivering faster recovery and better short-term quality of life — a genuine trade, not a free win, and a reminder that "minimally invasive" is not automatically "safer." Its vaginal arm was underpowered and could not separate vaginal from laparoscopic on complications. The current Cochrane review (Pickett 2023) resolves the picture across 63 trials: vaginal beats abdominal outright, laparoscopic beats abdominal on recovery and wound morbidity but at the price of more ureteric injury (OR ~2.2), and vaginal and laparoscopic are broadly comparable with vaginal faster to perform. So the hierarchy — vaginal, then laparoscopic, then open — is a reading of trial data, and the ureteric-injury trade-off is the substance of it.

Second, minimally invasive surgery is not a single verdict — it depends on the disease. This is the central nuance of the objective. For benign disease and for endometrial cancer, minimally invasive surgery is right: the LACE trial found laparoscopic hysterectomy non-inferior to open for disease-free survival in early endometrial cancer, with less morbidity. For early cervical cancer it is wrong: the LACC trial found minimally invasive radical hysterectomy roughly quadrupled the risk of recurrence or death (disease-free survival hazard ratio 3.74) and halved disease-free survival, reversing global practice almost overnight. Generalising either way — "MIS is always better" or "MIS is dangerous in cancer" — is the error. The correct, defensible position is disease-specific: de-escalate the wound in benign and endometrial disease, but operate open on invasive cervical cancer because the mechanism of harm (tumour spillage, gas dissemination) only exists there.

Third, robotic surgery is the live cost-and-equity controversy. The robot's real advantages are ergonomic and technical — three-dimensional vision, wristed instruments with seven degrees of freedom, tremor filtering, and a seated console that helps in deep, narrow or obese pelvises and in long complex dissections. But for the bread-and-butter operations the comparison is against conventional laparoscopy, and there the randomised evidence (Sarlos) and the Cochrane synthesis are blunt: outcomes are equivalent, operating time is if anything longer, and cost is substantially higher. The controversy is therefore not clinical but distributive: in a resource-limited health system, is it defensible to spend on a platform that does not improve patient outcomes over an existing one, when that money could equip district units with the basic laparoscopic capacity they lack? The genuine niche is the complex, deep-pelvis, obese or oncological case where conventional laparoscopy is hard; there is no outcome benefit for routine work; the spend is an equity decision rather than a technology one; and the robot does not rescue the LACC verdict, since the robotic arm of cervical-cancer practice was abandoned along with the laparoscopic.

The current edge of the field sharpens the same tension. Vaginal natural-orifice transluminal endoscopic surgery (V-NOTES) and single-port laparoscopy are spreading as "scarless" approaches, but Cochrane 2023 is explicit that, like robotics, they have no demonstrated patient benefit over conventional laparoscopy and need further evaluation — they are not yet established progress. Running underneath all of this is a quieter, genuinely topical debate about the cost and environmental footprint of single-use energy devices and robotic consumables: advanced vessel-sealers and stapler reloads are disposable, expensive and a meaningful source of theatre waste, and there is a growing push — relevant to a cost-constrained, climate-exposed South African service — to justify each disposable against a reusable alternative rather than adopt it by default. The defensible stance is the same one that governs route and robot: adopt for a demonstrated benefit, not for novelty, and count the cost honestly.

Landmark trials & key evidence

A worked number from the trial data: eVALuate's abdominal arm gave a laparoscopic major-complication rate of 11.1% versus 6.2% for open — an absolute increase of 4.9%, so the number needed to harm is 1/0.049 ≈ 20: roughly one extra major complication for every twenty women taken laparoscopically rather than open in that trial era. The point is not that laparoscopy is bad — recovery and quality of life favoured it — but that the route decision is a quantified trade, and the modern resolution (Cochrane) is that the vaginal route sidesteps much of that trade entirely, which is why it sits at the top of the hierarchy.

Worked viva — defending a route

Consider a 46-year-old para 3 at a regional hospital with heavy menstrual bleeding from a 12-week-size fibroid uterus, failed medical management, wanting a hysterectomy. The uterus is mobile with reasonable descent; the adnexa are normal. The management of route and energy runs:

1. Apply the hierarchy to her. Benign disease, so the route hierarchy applies. She has a mobile uterus with descent, normal adnexa and an operable size, so a vaginal hysterectomy is the preferred route — it has the best outcomes for benign disease and avoids both the abdominal wall and the longer ureteric exposure of laparoscopy. If on examination under anaesthesia the descent or access is inadequate, the next choice is laparoscopic, not open, accepting its higher ureteric-injury risk; open is reserved for if neither is safe.
2. The evidence. Cochrane shows vaginal superior to abdominal and comparable to laparoscopic with shorter operating time; eVALuate shows laparoscopy trades more major complications for faster recovery, which is why it is not the default when a vaginal route is feasible.
3. The safety anatomy. Whichever route, protect the ureter — it crosses under the uterine artery about 1.5–2 cm lateral to the cervix — by securing pedicles close to the uterus and, laparoscopically, identifying and lateralising it before applying energy.
4. Use energy deliberately. For haemostasis, bipolar or a vessel-sealing device rather than high-voltage monopolar coag, activate only with the whole tip in view, check insulation, avoid open-circuit activation and metal-isolated cannulae to prevent capacitive coupling, and keep a thermal margin from bowel and ureter.
5. The malignancy caveat and the system. If anything suggested an occult uterine malignancy, do not power-morcellate. And the deliverable route depends on the regional theatre's laparoscopic capacity and the operator's credentialing on the day.
6. If the pathology were cancer. Had this been an invasive cervical cancer, the logic reverses — open radical hysterectomy, because LACC showed minimally invasive radical hysterectomy quadruples recurrence risk.

Exam traps & red flags

• Defaulting to "laparoscopic = best." eVALuate shows laparoscopy carries more major complications than open for benign disease; the evidence-based top of the hierarchy is vaginal, not laparoscopic. Reaching for the laparoscope when a vaginal hysterectomy is feasible is the wrong instinct.
• Generalising the MIS verdict across cancers. Minimally invasive surgery is right for benign and endometrial disease (LACE) and wrong for early cervical cancer (LACC). "MIS is fine for all gynae cancer" and "open for all cancer" are both wrong — the answer is disease-specific.
• Offering robotic/laparoscopic radical hysterectomy for cervical cancer. Post-LACC this is a clear error; open radical hysterectomy is standard, and the robot does not rescue it.
• Selling robotics as outcome-superior. For routine benign work it is equivalent to laparoscopy at higher cost (Sarlos, Cochrane); the honest argument is a niche-and-equity argument, not a clinical-superiority one.
• Power-morcellating an undiagnosed uterus. Morcellating an occult leiomyosarcoma disseminates and upstages it; the malignancy question must be settled before any morcellation.
• The "no one touched the bowel" thermal injury. A delayed bowel perforation days after laparoscopy is the signature of capacitive coupling, direct coupling or insulation failure — stray monopolar energy, not a missed mechanical injury. Prevent it by device discipline, not by assuming the field was clean.
• Forgetting the ureter in the energy plan. Lateral thermal spread seals beyond the visible blanch; energy applied to the uterine pedicle without first lateralising the ureter risks a thermal stricture that presents late.
• Letting "best route" ignore the site. A route that is unavailable, or that exceeds the surgeon's credentialing, or that the patient cannot physiologically tolerate (steep Trendelenburg, prolonged pneumoperitoneum) is not the right route for that patient — name the deliverable one.

Evidence anchors

• eVALuate study — Garry et al., BMJ 2004
• Surgical approach to hysterectomy for benign gynaecological disease — Pickett et al., Cochrane Database Syst Rev 2023
• LACC trial — Ramirez et al., N Engl J Med 2018
• LACE pelvic-floor substudy (confirming the LACE trial design and result) — Higgs et al., Am J Obstet Gynecol 2018
• Robotic compared with conventional laparoscopic hysterectomy: a randomized controlled trial — Sarlos et al., Obstet Gynecol 2012
• ACOG Committee Opinion No. 701 — Choosing the Route of Hysterectomy for Benign Disease, Obstet Gynecol 2017
• Principles and safety measures of electrosurgery in laparoscopy — Alkatout et al., JSLS 2012
• South Africa NDoH / public-sector context — laparoscopic capacity, robotic platforms and brachytherapy are concentrated at academic and tertiary centres; the appropriate route is also the route the receiving facility can safely deliver.
• AAGL guidance on electrosurgical safety and the morcellation hazard (no single stable URL) — endorses the MIS-first hierarchy with surgeon credentialing and cautions against unexamined robotic expansion.